Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients
12 juil. 2022 11h23 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J, July 12, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announces that its novel liposomes reached a positive...
Silo Pharma Expands License Agreement and Patent Portfolio
23 juin 2022 08h05 HE
|
Silo Pharma, Inc.
Silo Enters into Commercial Evaluation License Agreement for Next Generation Liposomes Therapeutics Would Target Multiple Diseases Including Auto Immune Disorders ENGLEWOOD CLIFFS, N.J., June ...
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study
19 mai 2022 08h11 HE
|
Silo Pharma, Inc.
Study is examining effects of Psilocybin on Inflammatory MarkersENGLEWOOD CLIFFS, N.J., May 19, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical...
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study
20 avr. 2022 08h10 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study
31 mars 2022 08h10 HE
|
Silo Pharma, Inc.
ENGLEWOOD CLIFFS, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Extends Exclusive Option Agreement for Homing Peptides
03 févr. 2022 08h22 HE
|
Silo Pharma, Inc.
Company Analyzing Efficacy of Novel Joint Homing Peptide ART-1 for Rheumatoid Arthritis and inflammation Englewood Cliffs NJ, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTC QB: SILO), a...
Silo Pharma, Inc. Engages Donohoe Advisory to Assist with its Efforts to Obtain a Listing on a National Stock Exchange
14 déc. 2021 08h07 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, announced...
Silo Pharma Announces Grant of U.S. Patent For its Novel CNS Homing Peptide
02 déc. 2021 08h10 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic announced the...
Silo Pharma and Strategic Partner Zylo Therapeutics Begin Development Process for Novel Ketamine Loaded Z-Pods
18 nov. 2021 09h45 HE
|
Silo Pharma, Inc.
Englewood Cliffs NJ, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO) a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...
Silo Pharma Reports Third Quarter Results and Operating Highlights
11 nov. 2021 08h09 HE
|
Silo Pharma, Inc.
Englewood Cliffs, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today...